38.14 +0.40 (1.06%)
Pre-Market: 4:43AM EDT
|Bid||38.16 x 2900|
|Ask||38.24 x 1200|
|Day's Range||37.55 - 37.82|
|52 Week Range||30.20 - 39.18|
|PE Ratio (TTM)||114.36|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.05|
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / QIAGEN NV (NYSE: QGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 9:00:00 AM Eastern Time. To listen ...
Day-one lab readiness speeds commercialization and reimbursement in personalized medicine
Frankfurt Prime Standard: QIA) today announced that its careHPV™ Test, one of the only molecular diagnostics for high-risk human papillomavirus (HPV) designed to screen women in low-resource settings, has been added to the World Health Organization (WHO) list of prequalified in vitro diagnostics (IVDs). HPV is the primary cause of cervical cancer, so screening women for the presence of the virus is a critical aspect for prevention and early treatment of the deadly cancer.
Qiagen (QGEN) delivered earnings and revenue surprises of 3.13% and 0.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Venlo, Netherlands-based company said it had net income of 16 cents. Earnings, adjusted for non-recurring costs, came to 33 cents per share. The results exceeded Wall Street expectations. ...
Collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB detection
QIAGEN N.V. plans as previously announced to release its report on results for the second quarter 2018 on Tuesday, July 31 shortly after 22:00 Central European Time / 16:00 Eastern Daylight Time .
QIAGEN N.V. today introduced seamless next-generation sequencing solutions for a wide range of hereditary diseases on the GeneReader NGS System, the complete Sample to Insight NGS solution for any lab worldwide.
This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investingRead More...
WallStEquities.com has initiated research reports on the following Services stocks: CareDx Inc. (CDNA), Myriad Genetics Inc. (MYGN), QIAGEN N.V. (QGEN), and Nxt-ID Inc. (NXTD). Brisbane, California headquartered CareDx Inc.'s stock finished Wednesday's session 5.51% lower at $14.74 with a total trading volume of 569,113 shares, which was higher than their three months average volume of 518.93 thousand shares. The Company's shares are trading above their 50-day and 200-day moving averages by 26.99% and 101.82%, respectively.
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
QIAGEN N.V. today announced that it welcomes new guidelines from the American Academy of Pediatrics that recommend screening at-risk children as young as two years old for latent tuberculosis infection.
QIAGEN (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN N.V. today announced a partnership with Freenome, a leading artificial intelligence genomics company, to accelerate the development and commercialization of next-generation sequencing tests to enable precision medicine in cancer treatment.
A Relative Strength Rating upgrade for Qiagen shows improving technical performance. Will it continue?
QIAGEN today welcomed the First Edition of the World Health Organization’s (WHO) Essential Diagnostics List, which endorses the use of interferon gamma release assays (IGRAs) for the diagnosis of latent TB infection. The inclusion on the list comes as the WHO and other organizations like the US Centers for Disease Control (CDC), the International Panel Physicians Association (IPPA) and others have recommended to include IGRA’s such as QuantiFERON-TB Gold Plus. The World Health Organization (WHO) published the first edition of the Model List of Essential In Vitro Diagnostics (EDL) in May 2018, in recognition that IVDs are an essential component to advance universal health coverage, address health emergencies, and promote healthier populations.